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Loss of Synovial flu d lubrication
properties
HYALURONIC ACID
• Synthesized by synoviocytes (B)
• Released into the synovial space 
• HA belongs to the family of glycosaminoglycans
• HA is composed of 1000s of repeating disaccharide units
(N-acetylglucosamine and glucuronic acid) 
• A long polysaccharide chain of different length with a high molecular weight
• Accumulates on cartilage and ligament surfaces (boundary-layer lubrication)
“Viscosupplementation is the process that restores the normal
rheological environment in the synovial fluid, synovial
tissue…and reestablishes the protection, lubrication, shock
absorption and barrier effects.”









 Rheologic properties of the 
synovial fluid (visco-elastic)
 Shock absorbing (cushion)
 Lubrication
Gigante A. and Callegari L. Rheumat. Intern. 2010; 31 (4): 427-444.
Strauss E.J. et al. Am. Journ. Sports Med. 2009; 37 (8): 1636-1644.
Vitanzo P.C and Sennett B.J. Am. Journ. Orthopedics 2006; 421-428.
Altman R.D. et al. Osteoarthritis & Cartilage 2004: 12: 642-649.






• The clinical benefits of intra-articular HA (e.g. 
restoration synovial cell metabolism, normalization 
HA biosynthesis) that go well beyond the physical 
lubricant/cushioning effect are defined as 
VISCOINDUCTION.
•Viscoinduction ensures that the effect is maintained 
for several months despite the short half-life of intra-
articular HA 
Gigante A. and Callegari L. Rheumat. Intern. 2010; 31 (4): 427-444.





























High MW HA (>500kDa)
↑HA synthesis
↓Leukocytes migration and proliferation







• Molecular weight: 0.7 to 92 Mda
• Concenration: 0.8 to 2%
• Prize : 0.83 to 4.13 € per mg.
• Chemical form: linear or cross-linked
• Origin : bacterial or animal
• Injection protocol: multiple or mono
HA in France in 2015









Adant Sankyo 2.5 (1) 0.9 – 1.2 5 100 1.33
Arthrum LCA 2 (2) 2.4 3 100 0.83
Durolane Genévrier 3 (2) 92 1 230 3.83
Euflexxa Grunenthal 2 (1) 3 3 120 2
Go-On Rottapharm 2.5 (1) 1.4 3 100 1.33
HappyCross LABRHA 2 (1.6) 1.5 1 159 1.71
Hyalgan Expanscien
ce
2 (1) 0.5-0.7 3-5 88.32 1.47
Ostenil TRB 
Chemica
2 (1) 1.2 3-5 100 1.66







2 (1) 1.6 3 100 1.66
Synvisc One Sanofi 6 (0.8) 6 1 198.5 4.13
Mono-injection
Trade name concentration
Synvisc One® 6 ml/48 mg
Durolane 3 ml/20 mg
Arthrum 2.5%® 3 ml/25 mg
Coxarthrum 2.5%® 3 ml/50 mg
Ostenil Plus® 2 ml/mannitol
Synocrom Forte One 4 ml/ 2%
Happy Cross® 2.2 ml/cross linked/mannitol
 Cross-linked
 Increased concentration
 Anti-oxidant (sorbitol or mannitol)
Antioxidant to protect HA
Trade name Company Form Injection
protocol
Indication [HA&AO] AO 
molecule










HappyVisc® LABRHA Linear 3/ 2 ml Knee 1.55 %
3.5 %
Mannitol
Ostenil Plus® TRB 
Chemedica








APTISSEN Linear 1-3/ 2ml knee 2 %
4 %
Sorbitol
IAHA has a moderate effect on knee OA 
symptoms OARSI meta-analysis
(Zhang et al, 2010)
ES Pain ES Function
Acetominophen 0.14 (0.05,0.23) 0.09 (-0.03,0.22)
Diacerein 0.24 (0.08, 0.39) 0.14 (0.03, 0.26)
NSAIDs 0.29 (0.22,0.35) -
Aerobic 0.52 (0.34; 0.70) 0.46 (0.25, 067)
Glucosamine
Sulfate
0.58 (0,30, 0.87) 0.07 (-0.08,0,021)
IAHA 0.60 (0.37, 0,83) 0.61 (0.35,0.87)
Chondroitin sulfate 0.75 (0.50, 1.01) -
IAHA effect size is superior to  NSAIDS with less GI adverse events
HA improves pain and function in knee OA
*All Studies
ES < 0.2 = None
ES 0.2 – 05 = Weak
ES 0.5 – 08 = Moderate









Zhang W. et al. Osteoarthritis & Cartilage 2010; 18: 473-475.
Knee OARSI GUIDELINES
ES Pain
2 weeks In favour of IA Corticosteroids 0.39 (0.12-0.65)
4 weeks = 0.01 (-0.21,0.23)
8 weeks In favour of IAHA 0.22 (-0.5 ,0.49)
12 weeks In favour of IAHA 0.35 (0.03, 0.66)
Comparing with intra-articular corticosteroids, 
benefits last generally longer! 
Knee: HA in recent guidelines
Society Guidelines
ACR (2012) American College of 
Rheumatology
« Conditionnally recommended to not 
use »
AAOS (2013) American Association of 
Orthropaedic Surgeons
« Not recommended »
NICE (2014) National Institute for Health
and Clinical Excellence
« Do not offer intra-articular injection 
of hyaluronan for the management of 
OA »
OARSI (2014) Osteoarthritis Research
Society International
« Uncertain » let to the appreciation of 
the physician
« …iatrogenesis due to the overuse of NSAIDS, paracetamol and corticostéroids
infiltration… » Letter of the « Section arthrose » of the French Society of 
Rheumatology to CNEDIMTS







Patient education, physical and
occupational Therapy, weight




Primarily indicated for «end stage » OA
GI bleeding or other complications
CV risks
Renalr complications












Patient education, physical and
occupational Therapy, weight




Primarily indicated for «end stage » OA
GI bleeding or other complications
CV risks
Renalr complications






→Treatment of symptoms associated with OA
• CONTRAINDICATIONS
→On-going joint inflammation (active synovitis)




→ Allergy to poultry
Viscosupplementation
• Predictors of good outcome
→Mild to moderate joint deformities
→Absence of large synovial effusion
→Well-preserved periarticular muscle mass
→Minimal joint instability
• Predictors of good outcome
→ BMI > 30
→K &L 4 No joint space
Viscosupplementation
Conclusions
• IAHA is efficient and well tolerated
• The efficacy is moderate on pain and function
• Prolonged effect compared to corticosteroids
• The injection protocol should be assessed and 
respected
• Should be favor US guidance 
• Indication and efficacy should be evaluated at 























So…What’s about the future?
Perhaps not only a dream!
Perspectives
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